Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Escalating Dose Study of CT-322, a VEGFR-2 Antagonist, as Monotherapy in Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma

NCT00374179 is registered in ClinicalTrials.gov with Adnexus, A Bristol-Myers Squibb R&D Company as lead sponsor.

NCT NCT00374179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00374179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Escalating Dose Study of CT-322, a VEGFR-2 Antagonist, as Monotherapy in Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma
Lead sponsor
Adnexus, A Bristol-Myers Squibb R&D Company
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2006
Completion date
February 28, 2009
Enrollment
40 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer